Miyazaki Nanami L, Furusawa Aki, Choyke Peter L, Kobayashi Hisataka
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cancers (Basel). 2023 Oct 24;15(21):5117. doi: 10.3390/cancers15215117.
Head and neck squamous cell carcinoma (HNSCC) contribute to a significant global cancer burden. Developments in current therapeutic approaches have improved patient outcomes but have limited efficacy in patients with unresectable and/or recurrent HNSCC. RM-1929 near-infrared photoimmunotherapy (NIR-PIT) is an emerging treatment that is currently being investigated in a Phase III clinical trial and has been conditionally approved for the treatment of unresectable and/or recurrent HNSCC in Japan. Here, we collect a series of case reports and clinical trial data to assess the efficacy of RM-1929 NIR-PIT. Disease control rates ranged from 66.7 to 100% across these studies, and overall response rates ranged from 43.3 to 100%, suggesting positive clinical outcomes. Low-grade postoperative localized pain and edema were the most frequently reported side effects, and preliminary reports on quality of life and pain levels suggest that RM-1929 NIR-PIT does not significantly decrease quality of life and is manageable with existing pain management strategies, including opioids. These preliminary data in real-world use of RM-1929 NIR-PIT show that it is a well-tolerated therapy that has clinically meaningful outcomes for patients with unresectable and/or recurrent HNSCC.
头颈部鳞状细胞癌（HNSCC）在全球造成了重大的癌症负担。当前治疗方法的发展改善了患者的治疗效果，但对于不可切除和/或复发性HNSCC患者的疗效有限。RM - 1929近红外光免疫疗法（NIR - PIT）是一种新兴的治疗方法，目前正在进行III期临床试验，并已在日本获得有条件批准用于治疗不可切除和/或复发性HNSCC。在此，我们收集了一系列病例报告和临床试验数据，以评估RM - 1929 NIR - PIT的疗效。在这些研究中，疾病控制率在66.7%至100%之间，总体缓解率在43.3%至100%之间，表明临床结果良好。术后低度局部疼痛和水肿是最常报告的副作用，关于生活质量和疼痛程度的初步报告表明，RM - 1929 NIR - PIT不会显著降低生活质量，并且可以通过包括阿片类药物在内的现有疼痛管理策略进行控制。这些关于RM - 1929 NIR - PIT实际应用的初步数据表明，它是一种耐受性良好的治疗方法，对不可切除和/或复发性HNSCC患者具有临床意义的治疗效果。
